Basic Female Cialis Information

• INN (International Nonproprietary Name): Tadalafil.
• Brand Names Available In United Kingdom: Tadalafil is best known as Cialis® (Eli Lilly) and as Adcirca® for pulmonary arterial hypertension, with multiple generics available from manufacturers such as Cipla and Sun Pharma; packaging is typically the same yellow almond-shaped Cialis® tablets or generic blister packs of 1–28 tablets, and no distinct “Female Cialis” product is authorised.
• ATC Code: G04BE08 — phosphodiesterase type 5 (PDE5) inhibitor used in urogenital treatments.
• Forms & Dosages: Oral tablets commonly available in 2.5 mg, 5 mg, 10 mg, 20 mg and 40 mg strengths; Adcirca® film-coated 20 mg for PAH; no topical or female-specific formulations are authorised.
• Manufacturers In United Kingdom: Original product by Eli Lilly (Cialis®) with generics supplied by multiple international manufacturers and distributed through UK pharmacies and certified online suppliers.
• Registration Status In United Kingdom: Tadalafil is registered and authorised for erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension; there is no MHRA licence for female sexual dysfunction and no separate “Female Cialis” product.
• OTC / Rx Classification: Prescription-only (Rx) in the UK for authorised indications; some private clinics or e-pharmacies may offer off‑label prescribing for women.

Key Findings From Recent Trials

Major 2022–2025 Studies

People ask whether recent work finally proves a benefit for women.

Recent clinical work from 2022 to 2025 remains small, exploratory and heterogeneous.

Most of the strongest signals come from open‑label trials and small randomised controlled trials that tested tadalafil for female sexual dysfunction or specific symptoms such as arousal and lubrication.

Typical doses in these studies included 5 mg once daily and single doses up to 20 mg.

Occasional experimental work used single 40 mg doses for urethral pressure physiology studies rather than routine therapy.

Reported efficacy is modest and inconsistent across different study populations.

Some reports document small improvements in subjective arousal or measures of genital vasocongestion.

Other trials detected no clinically meaningful benefit on desire or overall sexual satisfaction.

Heterogeneity in diagnostic definitions, outcome measures and small sample sizes limits generalisability.

Main Outcomes

Overall, the evidence should be regarded as hypothesis‑generating rather than practice‑changing.

Where benefit was seen, it tended to be limited to vascular signs of arousal rather than desire or relational satisfaction.

Differences between sildenafil and tadalafil studies are mostly in half‑life and dosing strategy rather than demonstrated superiority for women.

Clinical translation is limited by psychological and hormonal drivers of female sexual dysfunction that a vasodilator cannot address alone.

UK clinicians are advised to view current trial findings cautiously and not to alter routine practice based on small trials alone.

Safety Observations

Adverse effects reported mirror the established tadalafil safety profile.

Common complaints included headache, flushing, nasal congestion, back pain and dyspepsia.

Serious events were rare in the reports but trials were underpowered to detect low‑frequency harms.

Overall evidence quality ranges from low to moderate and larger randomised controlled trials are required.

For the time being, treat findings as interesting but not definitive when counselling patients.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often want to know how the drug might help their symptoms.

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that relaxes small blood vessels in genital tissues.

By increasing local blood flow it can help physical signs of arousal such as genital vasocongestion and lubrication.

This vascular effect is why clinicians sometimes consider the drug for arousal‑related symptoms.

Scientific Breakdown

Tadalafil inhibits PDE5 which normally breaks down cyclic guanosine monophosphate (cGMP) in smooth muscle.

Inhibition leads to increased cGMP and prolonged nitric oxide–mediated vasodilation in genital vasculature.

Compared with sildenafil, tadalafil has a longer half‑life which makes daily low‑dose regimens feasible.

Mechanistic plausibility exists for vascular contributors to female sexual dysfunction, but it does not address psychological or endocrine drivers directly.

Pharmacokinetics (Brief)

Tadalafil is available as oral tablets in strengths from 2.5 mg to 40 mg and as a 20 mg film‑coated tablet for PAH under Adcirca®.

Absorption is reliable with or without food and onset and duration vary by dose.

In female investigational work regimens ranged from single 20–40 mg doses to daily 5 mg therapy in small trials.

Longer half‑life supports once‑daily dosing options that differ from sildenafil’s shorter action.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Tadalafil is licensed in the UK for erectile dysfunction and benign prostatic hyperplasia, and as Adcirca® for pulmonary arterial hypertension.

MHRA and EMA approvals do not include female sexual dysfunction as an authorised indication.

Tadalafil remains a prescription‑only medicine in the UK for authorised uses.

Notable Off‑Label Trends

Although no formal “Female Cialis” product exists, private clinics and online pharmacies sometimes market standard tadalafil tablets to women.

Packaging used for these sales is the same as authorised Cialis® or generic tablets.

Prescribers considering off‑label use should document informed consent, perform a baseline assessment and record the clinical rationale.

NHS prescribing for female sexual dysfunction is uncommon and generally not recommended unless stronger evidence emerges.

Dosage Strategy

General Dosing

For reference, common male regimens are on‑demand 10–20 mg or daily 2.5–5 mg and PAH dosing is 40 mg daily.

Female investigational regimens have been opportunistic and small in scale.

The most commonly reported approaches in trials are 5 mg once daily and single doses up to 20 mg.

Condition‑Specific Dosing

In small studies of sexual dysfunction the most frequent schedules were 5 mg once daily or single 10–20 mg doses.

Antidepressant‑induced sexual dysfunction trials have reported single or repeated 20 mg doses in very limited work.

Urethral and voiding physiology studies have explored single 40 mg doses experimentally.

Practical UK advice is to start low and reassess benefit and adverse effects after a defined trial period of several weeks.

Avoid PAH doses unless there is a clear indication and appropriate monitoring.

Safety Protocols

Contraindications

Absolute contraindications include known hypersensitivity to tadalafil and concurrent nitrate therapy because of risk of severe hypotension.

Severe hepatic or renal impairment and unstable cardiovascular disease are listed contraindications.

Retinitis pigmentosa and concurrent use of other PDE5 inhibitors represent important cautions.

Adverse Effects

Common adverse effects are headache, facial flushing, nasal congestion, back pain and dyspepsia.

Less common effects include dizziness, mild visual disturbances and urinary complaints.

Overdose presentations such as hypotension, syncope or sudden vision or hearing loss require urgent medical assessment.

Clinical governance should include baseline cardiovascular risk assessment and thorough medication reconciliation for nitrates and strong CYP3A4 inhibitors.

Follow MHRA guidance and local formularies when prescribing off‑label in the UK.

Interaction Mapping

Food Interactions

Tadalafil absorption is not significantly affected by food and it may be taken with or without meals.

Advise moderation of alcohol because excess drinking can worsen hypotension and side effects such as dizziness or flushing.

Drug Combinations To Avoid

Never combine tadalafil with nitrates in any form due to the risk of life‑threatening hypotension.

Exercise caution when combining tadalafil with alpha‑blockers because of orthostatic hypotension risk.

Strong CYP3A4 inhibitors such as ritonavir or ketoconazole increase tadalafil exposure and may necessitate dose adjustment or alternative therapy.

Concurrent PDE5 inhibitors are contraindicated.

Ask patients about recreational drugs and herbal supplements like L‑Arginine or ginseng, as co‑use is common and safety evidence varies.

Patient Experience Analysis

Survey Data

Formal patient‑reported outcomes in women are sparse and the available data are mixed.

Some small trials and clinic series report improved genital response or reduced discomfort for a subset of women.

Many women report no meaningful change in desire or overall sexual satisfaction.

Quality‑of‑life measures and partner factors are often not measured in these studies, limiting interpretation.

Forum Trends

Online forums and telemedicine reviews commonly refer to “Female Cialis” and describe highly variable efficacy.

Anecdotal accounts often emphasise headaches and flushing as common downsides.

Many users seek off‑label prescriptions from private clinics or e‑pharmacies and express concern about inconsistent dosing and lack of long‑term data.

Clinicians should manage patient expectations and address psychological, relational and hormonal contributors in parallel with any drug trial.

Distribution & Pricing Landscape

Tadalafil is sold as Cialis® and Adcirca® and as many generics from manufacturers such as Cipla and Sun Pharma.

Pack sizes commonly range from single tablets up to 28 tablets in blister packs.

In the UK tadalafil is prescription‑only and community pharmacies dispense authorised products.

Private telemedicine clinics and e‑pharmacies sometimes market tadalafil for women under “Female Cialis” labels even though packaging is identical to standard tablets.

Branded Cialis® typically carries a premium price while generic tadalafil is considerably cheaper per tablet.

NHS formulary use for female indications is rare and most off‑label use occurs via private prescriptions.

When sourcing online, check MHRA guidance and pharmacy certification to reduce the risk of counterfeit products.

In our online pharmacy, female cialis is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison (Concise)

Flibanserin (Addyi®) is approved for premenopausal hypoactive sexual desire disorder and acts centrally on neurotransmitters with daily dosing and specific monitoring requirements.

Bremelanotide (Vyleesi®) is an on‑demand subcutaneous option for premenopausal HSDD with a different adverse‑effect profile.

Sildenafil has also been used off‑label for female arousal issues but has a shorter half‑life than tadalafil.

Hormonal therapies such as oestrogen or testosterone are effective when an endocrine deficit is identified but require baseline testing and risk discussion.

Pros And Cons

PDE5 inhibitors including tadalafil are plausible choices when vascular deficits are suspected but they deliver inconsistent effects on desire and satisfaction.

Addyi and Vyleesi target desire more directly but come with specific indication criteria and monitoring considerations.

Hormones work when clinically indicated, particularly postmenopausally, but are not suitable for everyone.

Choice should be individualised and based on a validated diagnosis and shared decision making.

Regulatory Status

International Perspective

The US FDA approves tadalafil for male erectile dysfunction and for pulmonary arterial hypertension (Adcirca®) but not for female sexual dysfunction.

EMA and other regulators follow comparable indication restrictions.

United Kingdom Specifics

The MHRA does not licence a product as “Female Cialis” and tadalafil remains prescription‑only for authorised indications.

Routine NHS prescribing for female sexual dysfunction is not recommended and off‑label use requires local governance, documented consent and a clear risk/benefit assessment.

Prescribers should be aware of medico‑legal implications and ensure appropriate follow‑up and realistic patient expectations.

Consolidated FAQ

Rapid Answers Clinicians And Patients Ask

Is there a “Female Cialis”?

No — there is no separate regulatory product; standard tadalafil tablets are sometimes marketed off‑label for women but no female‑labelled formulation is authorised.

Does it work for women?

Evidence is limited and inconsistent; some small studies show modest improvements in vascular symptoms but not reliably in desire.

How is it obtained in the UK?

Tadalafil is prescription‑only; private clinics may offer off‑label prescriptions while NHS prescribing for FSD is uncommon.

What are typical safety counselling points?

Avoid nitrates, check for CYP3A4 interactions, start low and monitor for headache, flushing and back pain.

Pregnancy and breastfeeding?

Use is not recommended without specialist advice because safety data are limited.

Missed dose and overdose?

For missed daily doses take when remembered unless it is near the next dose; do not double up.

Overdose requires urgent medical help and may present with hypotension or fainting.

Visual Guide

Packaging & Forms (What To Show)

Show the classic Cialis® yellow almond‑shaped tablet and common generic blister packs of 2–28 tablets.

Include Adcirca® film‑coated 20 mg tablets for PAH to clarify the separate branding and indication.

Make it clear that no topical or female‑specific packaging is authorised.

Infographic Elements To Include

Schematic of mechanism: PDE5 inhibition → increased cGMP → vasodilation of genital blood vessels.

Dosage options to display: 2.5–40 mg with typical investigational female regimens of 5 mg daily and single 10–20 mg doses.

Contraindication icons: nitrates, severe hepatic/renal disease, unstable cardiovascular disease.

Common side‑effects list and storage temperature guidance: store at 25°C with permitted excursions 15–30°C.

Supply checklist for safe procurement: MHRA‑certified pharmacy, valid prescription, check batch and expiry.

Legend text: “No Licensed Female Formulation” and “Evidence Preliminary”.

Storage & Transport

Official Storage Instructions

Store tadalafil tablets at 25°C with permitted excursions between 15–30°C.

Keep tablets in the original blister to protect from moisture and light.

Handling Tips For Online Purchases And Travel

Verify the pharmacy’s credentials before buying online and retain original packaging and batch details.

Avoid exposing tablets to prolonged heat, freezing or humidity and keep medicines in hand luggage when travelling.

Dispose of expired or suspicious products at a pharmacy take‑back rather than in household waste.

Report packaging anomalies that might suggest counterfeit supply to the dispensing pharmacy and the MHRA.

Guidelines For Proper Use

Prescriber Checklist

Confirm indication and document the rationale for any off‑label use.

Review cardiovascular history and current medications, especially nitrates and strong CYP3A4 inhibitors.

Discuss the uncertain efficacy in women, known risks and obtain informed consent before starting therapy.

Plan follow‑up to assess efficacy and adverse events, typically after 4–12 weeks.

Patient Checklist

Follow the prescribed dose and regimen exactly, whether daily or as advised for on‑demand use.

Do not combine tadalafil with nitrates or other PDE5 inhibitors and moderate alcohol intake.

Report severe side‑effects such as chest pain, sudden vision or hearing loss, syncope or prolonged priapism-like symptoms immediately.

For missed daily doses take when remembered unless it is nearly time for the next dose; do not double doses.

Record outcomes using validated scales where possible and reassess continuation after a defined trial period.

Delivery Across United Kingdom

Concluding Notes For Clinicians

Ask whether the symptom profile is primarily vascular, hormonal or psychological before considering tadalafil off‑label.

Document baseline measures and obtain informed consent if prescribing for female sexual dysfunction.

Use validated outcome scales where possible and stop treatment if no meaningful benefit appears after a reasonable trial.

Remember that NHS routine prescribing for FSD is rare and local governance must be followed for off‑label use.

Consolidated References And Further Reading

All clinical and regulatory statements in this article are based on the current product monograph information and public regulatory summaries showing tadalafil authorised for male erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension, with no MHRA licence for female sexual dysfunction as of July 2025.

For supply and safety queries contact your local pharmacy or consult MHRA guidance before off‑label prescribing.